Mathew Anna T, Obi Yoshitsugu, Rhee Connie M, Chou Jason A, Kalantar-Zadeh Kamyar
Division of Nephrology, McMaster University, Hamilton, ON, Canada.
Division of Nephrology and Hypertension, School of Medicine, Harold Simmons Center for Kidney Disease Research and Epidemiology, University of California Irvine, Orange, California.
Semin Dial. 2018 Jul;31(4):343-352. doi: 10.1111/sdi.12701. Epub 2018 May 7.
While many patients have substantial residual kidney function (RKF) when initiating hemodialysis (HD), most patients with end stage renal disease in the United States are initiated on 3-times per week conventional HD regimen, with little regard to RKF or patient preference. RKF is associated with many benefits including survival, volume control, solute clearance, and reduced inflammation. Several strategies have been recommended to preserve RKF after HD initiation, including an incremental approach to HD initiation. Incremental HD prescriptions are personalized to achieve adequate volume control and solute clearance with consideration to a patient's endogenous renal function. This allows the initial use of less frequent and/or shorter HD treatment sessions. Regular measurement of RKF is important because HD frequency needs to be increased as RKF inevitably declines. We narratively review the results of 12 observational cohort studies of twice-weekly compared to thrice-weekly HD. Incremental HD is associated with several benefits including preservation of RKF as well as extending the event-free life of arteriovenous fistulas and grafts. Patient survival and quality of life, however, has been variably associated with incremental HD. Serious risks must also be considered, including increased hospitalization and mortality perhaps related to fluid and electrolyte shifts after a long interdialytic interval. On the basis of the above literature review, and our clinical experience, we suggest patient characteristics which may predict favorable outcomes with an incremental approach to HD. These include substantial RKF, adequate volume control, lack of significant anemia/electrolyte imbalance, satisfactory health-related quality of life, low comorbid disease burden, and good nutritional status without evidence of hypercatabolism. Clinicians should engage patients in on-going conversations to prepare for incremental HD initiation and to ensure a smooth transition to thrice-weekly HD when needed.
虽然许多患者在开始血液透析(HD)时具有大量残余肾功能(RKF),但美国大多数终末期肾病患者开始接受每周3次的常规HD治疗方案,很少考虑RKF或患者偏好。RKF与许多益处相关,包括生存、容量控制、溶质清除和炎症减轻。已经推荐了几种策略来在HD开始后保留RKF,包括HD开始的递增方法。递增HD处方是个性化的,以在考虑患者内源性肾功能的情况下实现充分的容量控制和溶质清除。这允许最初使用频率较低和/或时间较短的HD治疗疗程。定期测量RKF很重要,因为随着RKF不可避免地下降,HD频率需要增加。我们叙述性地回顾了12项观察性队列研究的结果,这些研究比较了每周两次与每周三次HD。递增HD与多种益处相关,包括保留RKF以及延长动静脉内瘘和移植物的无事件生存期。然而,患者的生存和生活质量与递增HD的相关性各不相同。还必须考虑严重风险,包括住院率和死亡率增加,这可能与长时间透析间期后的液体和电解质转移有关。基于上述文献综述和我们的临床经验,我们提出了可能预测递增HD方法有良好结果的患者特征。这些特征包括大量RKF、充分的容量控制、无明显贫血/电解质失衡、令人满意的健康相关生活质量、低合并疾病负担以及良好的营养状况且无高分解代谢证据。临床医生应与患者进行持续沟通,为递增HD开始做好准备,并确保在需要时顺利过渡到每周三次HD。